A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Breast Cancer
Interventions: DRUG: Entinostat|DRUG: Capecitabine
Sponsor: University of Virginia
Collaborators: Syndax Pharmaceuticals